1. Home
  2. ICU vs INTS Comparison

ICU vs INTS Comparison

Compare ICU & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICU
  • INTS
  • Stock Information
  • Founded
  • ICU 2018
  • INTS 2012
  • Country
  • ICU United States
  • INTS United States
  • Employees
  • ICU N/A
  • INTS N/A
  • Industry
  • ICU Biotechnology: Pharmaceutical Preparations
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ICU Health Care
  • INTS Health Care
  • Exchange
  • ICU Nasdaq
  • INTS Nasdaq
  • Market Cap
  • ICU 9.5M
  • INTS 8.4M
  • IPO Year
  • ICU N/A
  • INTS 2023
  • Fundamental
  • Price
  • ICU $0.66
  • INTS $0.24
  • Analyst Decision
  • ICU
  • INTS Strong Buy
  • Analyst Count
  • ICU 0
  • INTS 2
  • Target Price
  • ICU N/A
  • INTS $6.75
  • AVG Volume (30 Days)
  • ICU 5.7M
  • INTS 6.2M
  • Earning Date
  • ICU 08-12-2025
  • INTS 08-11-2025
  • Dividend Yield
  • ICU N/A
  • INTS N/A
  • EPS Growth
  • ICU N/A
  • INTS N/A
  • EPS
  • ICU N/A
  • INTS N/A
  • Revenue
  • ICU $428,000.00
  • INTS N/A
  • Revenue This Year
  • ICU $754.07
  • INTS N/A
  • Revenue Next Year
  • ICU $100.09
  • INTS N/A
  • P/E Ratio
  • ICU N/A
  • INTS N/A
  • Revenue Growth
  • ICU N/A
  • INTS N/A
  • 52 Week Low
  • ICU $0.31
  • INTS $0.19
  • 52 Week High
  • ICU $9.09
  • INTS $4.94
  • Technical
  • Relative Strength Index (RSI)
  • ICU 45.72
  • INTS 30.38
  • Support Level
  • ICU $0.53
  • INTS $0.32
  • Resistance Level
  • ICU $0.94
  • INTS $0.36
  • Average True Range (ATR)
  • ICU 0.10
  • INTS 0.03
  • MACD
  • ICU 0.01
  • INTS -0.00
  • Stochastic Oscillator
  • ICU 30.91
  • INTS 30.74

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: